Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BioAge Labs, Inc. due to alleged violations of federal securities laws related to misleading information about its STRIDES Phase 2 clinical trial [2][4]. Group 1: Company Overview - BioAge Labs, Inc. (NASDAQ: BIOA) completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share, including an additional 1.65 million shares purchased by underwriters [4]. - The company faced significant stock price decline following the announcement on December 6, 2024, that it would discontinue the STRIDES Phase 2 study of its drug candidate azelaprag due to liver transaminitis observed in subjects [5][6]. Group 2: Legal Proceedings - A federal securities class action has been filed against BioAge, with a deadline of March 10, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that BioAge and its executives provided false and misleading information regarding the safety of their investigational drug candidate [4]. Group 3: Investor Impact - Investors who suffered losses exceeding $75,000 in BioAge between September 26, 2024, and January 7, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1]. - The stock price of BioAge fell from $20.09 per share on December 6, 2024, to $4.65 per share by December 9, 2024, indicating a significant loss for investors [6].
Faruqi & Faruqi Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA